HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 23, 2024 10:30 ET
|
HiberCell, Inc.
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce...
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
May 28, 2024 08:00 ET
|
HiberCell, Inc.
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
April 05, 2024 10:00 ET
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
June 29, 2021 08:00 ET
|
HiberCell
NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J....
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
June 10, 2021 08:00 ET
|
HiberCell
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...
HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital
May 19, 2021 08:00 ET
|
HiberCell
Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company...